12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SAN-300: Phase I data

Data from 66 healthy volunteers in a double-blind, placebo-controlled, Australian Phase I trial showed that single doses of IV and subcutaneous formulations of SAN-300 were generally well tolerated. The most common adverse events with IV administration were mild or moderate headaches and infusion reactions. The most common adverse events with subcutaneous administration were headaches and mild injection-site reactions. Subjects received placebo,...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >